SD-OCT provides better quality images of chorodial osteoma

Article

Spectral domain-optical coherence tomography (SD-OCT) provides higher resolution images of chorodial osteoma compared with time domain-OCT, reveals a study published in the British Journal of Ophthalmology.

Spectral domain-optical coherence tomography (SD-OCT) provides higher resolution images of chorodial osteoma compared with time domain-OCT, reveals a study published in the British Journal of Ophthalmology.

Dr Paul T. Finger et al., The New York Eye Cancer Center, New York, USA, studied 11 chorodial osteoma patients in a retrospective chart review. The review included patient, clinical, ultrasonographic, photographic and SD-OCT imaging.

The results demonstrated that the mean basal diameters of tumours recorded by fundus photography and ultrasound imaging were 5.2 mm and 6.4 mm respectively. In two cases, tumours were SD-OCT hyporeflective, hyperreflective in two cases and SD-OCT isoreflective in seven cases. In four cases, the intrinsic reflectivity of the tumour was inhomogenous. Also, the remaining choroid was reduced by the tumour in eight patients. In five patients degenerative retinal changes were found.

The study gives a deeper insight into the pathophysiology and diagnosis of chorodial osteoma. The images provided by SD-OCT are deeper and are of a higher resolution compared to images provided by time domain-OCT.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.